APEX Labs a pharmaceutical company transforming the standard of mental health care with clinically proven psilocybin treatments,Our mission is to develop and commercialize clinically evaluated psilocybin-derived treatments to tackle the most critical unmet need in depression, anxiety, and PTSD among Veterans and the general population. Apex Labs received Health Canada approval of SUMMIT-90, a landmark double-blind, placebo controlled phase 2b study evaluating multiple doses of APEX-90 administered in-clinic with assisted psychotherapy for the treatment of severe depression within diagnosed PTSD. The 160 patient trial approval comes by way of a no objection letter received from Health Canada on April 14th, 2023 and the company aims to begin recruitment Q2 of 2023.APEX also has a micro-dose take home synthetic psilocybin drug asset, APEX-52 optimized for mild-to-moderate depression. The company recently completed a proof-of-concept trial meeting all clinical endpoints with no adverse events, and subsequently received approval for a 294 patient phase 2b study, PATHFINDER-52, the largest of its kind in the world.

My focus strategically is on clinical study, data capture and commercialization of innovative treatment approaches offering superior efficacy without the unwanted adverse event profile when addressing unmet medical need Therapeutic alteration of intestinal microbiota in conditions such as C. difficile infection, IBS and many other disease conditions is the focus of a great deal of clinical study yielding very promising resultsPharmaceutical grade cannabinoid (CBD) has demonstrated strong scientific evidence for its effectiveness in treating some of the cruelest childhood epilepsy syndromes and chronic pain, opioid addiction, anxiety and PTSD

Innovative, Deep-Learning AI Solutions, Developed from the Ground-Up for Medical use. emtelligent’s™ emtelliPro™ deep-learning engine uses proprietary, advanced artificial intelligence to structure the 80% of medical data that is currently stored as unstructured text data.

Reported to the CEO. Responsible for commercial marketing, sales and business analytics departments. Staff of up to 40 employees.

Private, health focused, digital strategy agency specializing in innovative digital health solutions.Responsible for leading company's expansion into the US.

Reported to the CEO. Responsible for commercial marketing, sales and business analytics departments (15 direct employees).

Reported to the EVP. Responsible for the development of short and longer term commercial strategy - managed business analytics and strategic marketing (5 direct employees)

Reported to the Global Vice President. Responsible for the development of global strategy and the successful global launches of new HIV drugs in Europe, AP, LA and Middle East & Western Africa regions.

Reported to the Global Vice President. Responsible for the development of global strategy for EPREX™ / PROCRIT™ around the world working closely with Johnson & Johnson country managers in Europe, AP, LA and MEWA regions.

Reported to the CEO. Responsible for commercial marketing, sales and medical affairs departments for the Specialty product portfolio in Canada (23 direct employees).